TXG - Canaccord sees solid Q3 earnings for medtech; likes Quanterix Natera Guardant
2023-10-29 17:28:12 ET
More on Guardant Health, Natera, etc.
- Natera: Cash Burn Remains A Concern
- Guardant Health: Peeling Back Economic Layers, Compressed Market Values Appear Justified
- Pacific Biosciences: Looks Appealing In The Fast-Growing Long-Read Sequencing Market
- Johnson & Johnson inks licensing deal with Quanterix for Alzheimer's testing
- Natera prevails in patent battle as Supreme Court denies CareDx appeal
For further details see:
Canaccord sees solid Q3 earnings for medtech; likes Quanterix, Natera, Guardant